Data Sheet (Cat.No.T75136)

TargetMol

Zomiradomide

Chemical Properties



CAS No. : 2655656-99-6

Formula: C45H48F3N7O6S

Molecular Weight: 871.97

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Zomiradomide is a PROTAC degradation agent targeting IRAK4, with oral bioavailability, and can also degrade Ikaros (IKZF1) and Aiolos (IKZF3), thereby inhibiting the NF-κB signalling pathway and activating the type I interferon signalling pathway, exhibiting anticancer activity against B-cell lymphoma.
Targets(IC50)	NF-κB,IFNAR,IRAK,PROTACs,IKZF
In vitro	**Method**: The diffuse large B-cell lymphoma (DLBCL) cell line OCI-Ly10 carrying the Myd88 L265P mutation was treated with various concentrations of Zomiradomide to assess its antiproliferative effect and determine the IC_{50} value. **Result**: Zomiradomide effectively inhibited the proliferation of OCI-Ly10 cells, with an IC_{50} of 11 nM. [2]
In vivo	**Method**: In OCI-Ly10 xenograft mouse models, Zomiradomide was administered orally at doses of 3-30 mg/kg once daily for 3 consecutive days to evaluate its antitumor effect. **Result**: Zomiradomide significantly inhibited tumor growth. [2]

Solubility Information

Solubility	DMSO: 150 mg/mL (172.02 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	2% DMSO+40% PEG300+5% Tween 80+53% Saline: 3 mg/mL (3.44 mM) *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1468 mL	5.7341 mL	11.4683 mL
5 mM	0.2294 mL	1.1468 mL	2.2937 mL
10 mM	0.1147 mL	0.5734 mL	1.1468 mL
50 mM	0.0229 mL	0.1147 mL	0.2294 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zeng S, et al. Current advances and development strategies of orally bioavailable PROTACs. Eur J Med Chem. 2023 Dec 5;261:115793.

Weiss MM, et al., Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma. J Med Chem. 2024 Jul 11;67(13):10548-10566.